These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 23958923)
1. Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system. Arndt C; Feldmann A; von Bonin M; Cartellieri M; Ewen EM; Koristka S; Michalk I; Stamova S; Berndt N; Gocht A; Bornhäuser M; Ehninger G; Schmitz M; Bachmann M Leukemia; 2014 Jan; 28(1):59-69. PubMed ID: 23958923 [TBL] [Abstract][Full Text] [Related]
2. Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts. Aliperta R; Cartellieri M; Feldmann A; Arndt C; Koristka S; Michalk I; von Bonin M; Ehninger A; Bachmann J; Ehninger G; Bornhäuser M; Bachmann MP Blood Cancer J; 2015 Sep; 5(9):e348. PubMed ID: 26383821 [TBL] [Abstract][Full Text] [Related]
3. T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia. Hoseini SS; Vadlamudi M; Espinosa-Cotton M; Tran H; Feng Y; Guo HF; Xu H; Cheung I; Cheung NV J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035113 [TBL] [Abstract][Full Text] [Related]
4. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. Cartellieri M; Feldmann A; Koristka S; Arndt C; Loff S; Ehninger A; von Bonin M; Bejestani EP; Ehninger G; Bachmann MP Blood Cancer J; 2016 Aug; 6(8):e458. PubMed ID: 27518241 [TBL] [Abstract][Full Text] [Related]
5. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Friedrich M; Henn A; Raum T; Bajtus M; Matthes K; Hendrich L; Wahl J; Hoffmann P; Kischel R; Kvesic M; Slootstra JW; Baeuerle PA; Kufer P; Rattel B Mol Cancer Ther; 2014 Jun; 13(6):1549-57. PubMed ID: 24674885 [TBL] [Abstract][Full Text] [Related]
6. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Aigner M; Feulner J; Schaffer S; Kischel R; Kufer P; Schneider K; Henn A; Rattel B; Friedrich M; Baeuerle PA; Mackensen A; Krause SW Leukemia; 2013 Apr; 27(5):1107-15. PubMed ID: 23178753 [TBL] [Abstract][Full Text] [Related]
7. Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia. Reusch U; Harrington KH; Gudgeon CJ; Fucek I; Ellwanger K; Weichel M; Knackmuss SH; Zhukovsky EA; Fox JA; Kunkel LA; Guenot J; Walter RB Clin Cancer Res; 2016 Dec; 22(23):5829-5838. PubMed ID: 27189165 [TBL] [Abstract][Full Text] [Related]
8. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Krupka C; Kufer P; Kischel R; Zugmaier G; Bögeholz J; Köhnke T; Lichtenegger FS; Schneider S; Metzeler KH; Fiegl M; Spiekermann K; Baeuerle PA; Hiddemann W; Riethmüller G; Subklewe M Blood; 2014 Jan; 123(3):356-65. PubMed ID: 24300852 [TBL] [Abstract][Full Text] [Related]
9. Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system. Arndt C; Feldmann A; Koristka S; Cartellieri M; Dimmel M; Ehninger A; Ehninger G; Bachmann M Prostate; 2014 Sep; 74(13):1335-46. PubMed ID: 25053443 [TBL] [Abstract][Full Text] [Related]
11. Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564, a bivalent bispecific CD33 x CD3 T cell engager. Eissenberg LG; Ritchey JK; Rettig MP; Patel DA; Vij K; Gao F; Smith V; Han TH; DiPersio JF PLoS One; 2024; 19(5):e0300174. PubMed ID: 38696390 [TBL] [Abstract][Full Text] [Related]
12. Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. Arndt C; von Bonin M; Cartellieri M; Feldmann A; Koristka S; Michalk I; Stamova S; Bornhäuser M; Schmitz M; Ehninger G; Bachmann M Leukemia; 2013 Apr; 27(4):964-7. PubMed ID: 23325142 [No Abstract] [Full Text] [Related]
14. CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells. Jitschin R; Saul D; Braun M; Tohumeken S; Völkl S; Kischel R; Lutteropp M; Dos Santos C; Mackensen A; Mougiakakos D J Immunother Cancer; 2018 Nov; 6(1):116. PubMed ID: 30396365 [TBL] [Abstract][Full Text] [Related]
15. The role of CD33 as therapeutic target in acute myeloid leukemia. Walter RB Expert Opin Ther Targets; 2014 Jul; 18(7):715-8. PubMed ID: 24750020 [TBL] [Abstract][Full Text] [Related]